Helus Pharma (HELP) vs Jade Biosciences (JBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Helus Pharma (HELP) has outperformed Jade Biosciences (JBIO) over the past year, gaining 88.2% versus a gain of 55.8%. Over five years, HELP leads with a -84.2% price change compared with -97.1% for JBIO. Jade Biosciences is the larger company by market cap ($915.2 million vs $862.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HELP | JBIO |
|---|---|---|
| Share price | $11.80 | $14.39 |
| Market cap | $862.11M | $915.17M |
| 1-day change | +10.07% | +1.70% |
| YTD return | +44.25% | -8.30% |
| 1-year return | +88.20% | +55.84% |
| 5-year return | -84.24% | -97.14% |
| EPS (TTM) | $-4.57 | $-1.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.15 | $28.00 |
| 52-week low | $3.76 | $8.36 |
| Distance from 52-week high | -22.11% | -48.61% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +237.54% | +248.37% |
| Average volume | 1.77M | 904.61K |
| Shares outstanding | 73.06M | 63.60M |
| Employees | 100 | 55 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HELP has outperformed JBIO by 32.4 percentage points over the past year.
About Helus Pharma
HELP stock →Helus Pharma Inc., doing business as Helus Pharma, operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Jade Biosciences
JBIO stock →Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
HELP vs JBIO FAQ
Which is bigger, Helus Pharma or Jade Biosciences?
Jade Biosciences (JBIO) is larger, with a market capitalization of $915.17M compared with $862.11M for Helus Pharma (HELP).
Which stock has performed better over the past year, HELP or JBIO?
HELP returned +88.20% over the past 12 months, compared with +55.84% for JBIO (price return, excluding dividends). Past performance does not predict future results.
Are Helus Pharma and Jade Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.